
compani
usd jul pm et
summari larg produc brand-nam prescript drug offer wide rang treatment
neurolog disord diabet cancer condit
price-to-earnings oper ep
risk assess reflect relentless effort
gener challeng compani brand-nam drug
intens competit brand drug maker
market share brand-nam indic
uncertainti relat drug develop regulatori
approv risk partial mitig divers
product portfolio drug gener
sale robust develop pipelin compani
typic drug phase later
stage regulatori approv approv pipelin
drug like fuel long-term sale growth even older
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
compani drop target
price ep estim
-- roughli line histor forward
price-to-earnings averag ep vs beat
consensu rais ep
estim
sale grew yoy drug
portfolio current balanc growth newer
drug reduc demand loss
exclus older one among top drug
perform well trulic diabet
sale grew yoy increas
volum even realiz price declin
quarter taltz psoriasi whose sale
jump yoy rise demand
strong perform need off-set
yoy declin ciali erectil disfunct
due gener competit yoy drop
humalog diabet due lower
price see attract upsid
sever big pharma peer
heavili concentr diabet
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president financ
compani
corpor overview compani fifth largest drug maker term revenu
lead develop drug wide rang therapeut area includ cardiovascular
endocrinolog immunolog neurosci oncolog
drug portfolio drug portfolio concentr larger peer view
half revenu come top six drug compani top-sel drug includ trulic
diabet billion sale total humalog diabet billion sale
total alimta lung cancer billion sale total ciali erectil dysfunct
billion sale total forteo osteoporosi billion sale total
humulin diabet billion sale total
critic drug compani like consist success new drug growth mode order
off-set older drug declin sale due loss exclus competit new
improv treatment exampl type declin erectil dysfunct drug ciali whose
sale peak around billion declin patent expir convers
trulic diabet still earli exclus period expir achiev rapid sale
growth offset declin ciali sale
next five year face sever key exclus expir hope off-set growth
newer drug critic upcom patent expir end data exclus period includ forteo
sale alimta sale cymbalta sale given
larg expect sale impact alimta lung cancer upcom loss exclus
focus major acquisit dollar promis develop asset oncolog detail major
develop section
research develop effort continu off-set declin sale older drug spend
heavili research develop keep new drug come pipelin
global drug market spend total billion repres total revenu
februari drug develop pipelin consist on-going clinic trial
variou phase total trial phase final stage human clinic trial
registr phase fda approv final regulatori review drug market phase
later trial new molecular entiti nme often greater market potenti
new indic trial intend expand treatment indic already-approv drug get
approv lung cancer drug approv new breast cancer indic
develop pipelin includ potenti new treatment wide rang condit includ
migrain diabet psoriasi pancreat cancer kidney diseas critic upcom pipelin event
includ potenti fda approv lasmiditan acut migrain galcanezumab cluster headach
potenti approv ramucirumab second-lin treatment hepatocellular cancer liver phase
data readout drug first-lin treatment lung cancer phase data readout
tanezumab sever pain indic
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care
major develop septemb began process divest anim health
segment estim oper profit initi public offer sold
busi compani divest rest segment exchang offer
complet march june paid billion acquir phase cancer drug
pegilodecakin keep focu grow oncolog portfolio februari acquir
loxo oncolog approxim billion purchas bring pipelin highli select
potenti medicin patient genom defin cancer
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate period adjust pre-tax
incom margin increas mainli due strong perform contain sg
cost remain roughli flat three-year period sale grew materi due
sale growth larg improv profit margin adjust pre-tax incom per share
grew three-year compound-annual-growth-rate compani conserv capit view
ebita-to-interest coverag around
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
outlook sub-industri
next year neutral expect
modest revenu growth
driven slowdown novel drug approv
activ potenti new price regul
neg partial off-set
upcom favor period patent
expir also
expect gener maker continu struggl
grow earn lower cost foreign
competit continu prosper
banner year new brand
drug fda see slowdown
total novel drug approv
fda signific
surg versu combin approv
growth sub-industri
versu averag
new drug launch appear slow
howev fda approv
novel drug year june
period also observ
yoy declin spend
pharmaceut think
portend effort maintain margin sluggish
revenu growth year ahead
pharmaceut also face increas
risk potenti new drug price regul
juli presid indic
administr work new rule set
govern drug price use intern
index accord wall street journal
studi govern health system develop
countri like england norway canada often
pay less major brand
 center medicar medicaid
servic think intern
index rule would like drive higher price
foreign market lower one
would like still neg
overal impact sub-industri revenu
administr effort date lower drug
price regul
success intern index
signific risk weigh outlook
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
posit brand drug sale
beyond brand firm make lion
share sub-industri market cap outlook
gener maker neg previous
anda would declin sever deflat
drove competitor industri
seem play
six-month move averag anda june
recent peak
longer think fewer competitor
enough stabil gener industri
howev india-bas gener maker
like take market share develop nation
firm due lower product cost --
india-bas produc oper
estim averag gross margin
versu top western
drop broader composit
year-to-d juli
pharmaceut
gain
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
analyst research note compani news
et cfra keep hold opinion share compani
drop target price ep
estim -- roughli line histor forward price-to-earnings averag ep
vs beat consensu rais ep estim
sale grew yoy
drug portfolio current balanc growth newer drug reduc demand
loss exclus older one among top drug perform well
trulic diabet sale grew yoy increas
volum even realiz price declin quarter taltz psoriasi
whose sale jump yoy rise demand strong perform
need off-set yoy declin ciali erectil disfunct due
gener competit yoy drop humalog diabet due lower
price see attract upsid sever big pharma peer
heavili concentr diabet see long-term
et cfra keep hold opinion share eli li
rais target in-lin peer forward
ep estim adjust ep vs
ahead estim aid lower-than-expect oper cost due
cost reduct effort improv product rais ep estim
ep estim sale rose
pharmaceut sale driven new product trulic taltz
cyramza basaglar also encourag pipelin advanc
phase trial tanezumab treat osteoarthr met three co-primari
endpoint empagliflozin treat diabet also met primari endpoint
announc spin elanco anim health unit ipo say
maxim after-tax valu sharehold view spin-off posit
anim health unit struggl past year soft sale /jeffrey
et cfra keep hold opinion share eli lilli
compani keep target price line
peer ep estim rais
ep estim ep vs
ahead estim sale aid fx benefit rose driven
increas demand new drug trulic talz
basaglar oper cost fell drive oper
margin bp diabet volum growth rose note continu
soft anim health expect growth unit
separ fda advisori panel recommend approv baricitinib treat
moderate-to-sever rheumatoid arthriti dosag
approv dosag safeti concern particularli pulmonari
embol deep vein thrombosi note dose approv
europ expect work fda dose believ
dose key gain market share /jeffrey loo cfa
pm et cfra keep hold opinion share compani
keep target ep
estim -- roughli line histor forward price-to-earnings averag ep
vs line consensu rais ep estim
keep sale grew yoy driven
growth volum partial off-set drop realiz price
growth led trulic diabet total sale yoy
drug experienc first sequenti sale declin sinc launch
indic us may last year abnorm high
growth face greater competit major drug perform
well humalog diabet yoy tougher competit
alimta sale lung cancer flat due gener entri europ
expect gener ep growth rapid growth
success newer drug balanc declin older one lose exclus
et cfra keep hold opinion share compani
lift target
ep estim -- roughli line histor forward price-to-earnings averag
ep vs line consensu lower ep
estim start sale yoy
driven growth volum partial off-set decreas price
neg currenc impact growth led diabet drug trulic
yoy basaglar yoy well psoriasi drug
taltz yoy robust demand growth three drug
account total sale year ago total revenu growth
hinder loss exclus ciali revenu howev
face new gener competit saw annual sale declin
expect gener revenu growth around rapid
growth success newer drug balanc declin older one without
compani rais target
ep estim line histor averag forward price-to-earnings ep
vs consensu rais ep estim
sale yoy higher
volum partial off-set lower averag price growth led
diabet drug trulic yoy psoriasi drug taltz
yoy robust demand also improv margin
quarter cog sg grow slower revenu
combin effect strong sale growth cost contain estim
yoy increas adj pre-tax incom pipelin encourag fda
approv emgal migrain treatment think
competit sever new migrain drug approv year june
acquisit phase pegilodecakin think promis orphan
drug pancreat cancer /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
compani
